AstraZeneca FluMist Supply Jumps With CDC's Seal Of Approval
Executive Summary
US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.
You may also be interested in...
FluMist Rejuvenated With CDC Advisory Panel Endorsement; Effectiveness Data Still To Come
US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.
FDA Supports FluMist Use, Releases Lots For 2016 Flu Season
Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.
Operation Warp Speed For Rare Diseases? US FDA Is Considering Pilot Programs
CBER director Peter Marks says the FDA may evaluate giving gene therapy products the ‘degree of responsiveness’ that COVID-19 vaccines received. In a discussion of the pandemic's effects on staff retention, CDER director Patrizia Cavazzoni says attrition rates are back to historical levels.